^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | MP0274 (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab
Published date:
11/03/2022
Excerpt:
A 37-year-old female patient presented in September 2012 with HER2+ amplified (immunohistochemistry 3+) stage IV (T1N3M1) cancer of the right breast, with liver, bone, and lymph node metastases...We report here, to our knowledge, the first demonstration of clinical proof of concept for MP0274, with a sustained clinical response in a young patient with metastatic breast cancer treated at a dose level that achieved the high and sustained MP0274 concentrations predicted for required potential efficacy, after failure on two prior lines of therapy, both including an anti-HER2 monoclonal antibody.
DOI:
10.1200/PO.22.00006
